ClinicalTrials.gg
CompletedNCT03690414Updated Feb 12, 2020

Evaluation of Short Term Use of Experimental Eye Drops BHVI2, 0.02% Atropine and BHVI2 Plus 0.02% Atropine Eye Drops

A Phase 1 interventional study of Experimental BHVI2 and Atropine sulfate 0.02% eye drops in Myopia, sponsored by Hai Yen Eye Care. Completed at 1 site in Vietnam. Open to participants aged 6 Years to 13 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-02-12.

Sponsored by Hai Yen Eye Care · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
52
Allocation
Randomized
Ages
6 Years to 13 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 54 studies testing atropine in Myopia — 17 open to participants now, 24 under way, 9 of them phase 3. Atropine · Myopia.

Enrollment
43rd of 54
52 · median 144
Started
2018
with 6 others
Phase 1
8 of 54
none open now
Registered
15th of 54
by date
Lead sponsor
2 of 54
Hai Yen Eye Care

Among the 54 studies testing atropine in Myopia, this one is the 43rd largest by enrollment, is one of 7 that started in 2018, is one of 8 in phase 1, and was the 15th registered.

Myopia

1,162 studies on the registry are indexed under Myopia; 228 are open to participants now.

Browse Myopia studies →

Open to participants now

17 of the 54 studies testing atropine in Myopia are open now, in 11 countries. Recruiting first, the newest first:

12 more — sign in →

By country, each count listing its studies:

All 17 open studies →

About atropine

Atropine: first FDA approval 1960 (LOMOTIL), first EMA approval 2025. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 122 Myopia studies recruiting now, 19 (16%) set no upper age limit and 102 (84%) stop at 75 or younger; 86 take children under 18; 53 take healthy volunteers.

This study: 6 Years to 13 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies testing atropine in Myopia, or all of them as a file.
02

Study summary

To assess the one-month ocular effects of nightly application of experimental BHVI2 and 0.02% atropine eye drops either alone or in combination, in children aged between 6 to 13 years old with myopia and randomized to use of experimental BHVI2 eye drops, 0.02% atropine eye drops, experimental BHVI2 plus 0.02% atropine eye drops.

Read the detailed description

Atropine was proven to be effective in controlling myopia. 7-methylxanthine was considered to play a role in slowing myopia. The experimental BHVI2 eye drops were proven to be safe for in-eye use in the trial that was conducted in Sydney, Australia. The investigators wish to evaluate the effects of experimental BHVI2 and 0.02% atropine eye drops either alone or in combination mainly on the pupillary and accommodative responses in children aged between 6 to 13 years old over a one-month period.

03

Conditions studied

  • Myopia

Browse trials for

Keywords

  • Myopia control
  • Atropine eye drops
  • Caffeine eye drops
  • Pupillary diameter
  • Accommodative responses
04

Who can participate

Ages eligible
6 Years to 13 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • be accompanied by a parent or guardian who is able to read and comprehend Vietnamese/English and give as demonstrated by signing a record of informed consent;
  • at baseline, be within the age range of 6 to 13 years old inclusive;
  • be diagnosed as myopic having spherical equivalent between -0.50 diopter and-6.00 diopter.
  • willing to comply with the applying eye drops once nightly at bedtime and follow the clinical trial visit schedule as directed by the Investigator.
  • be willing to comply with the wearing and clinical trial visit schedule as directed by the investigator;
  • have ocular findings deemed to be normal
  • vision correctable to at least 20/25 or better in each eye with spectacles

Exclusion criteria

Exclusion Criteria:

Subjects enrolled in the trial must NOT have:

  • Any pre-existing ocular irritation, allergic conjunctivitis, injury or condition, including infection or disease.
  • Any systemic disease that adversely affects ocular health e.g. diabetes, Graves disease, and auto-immune diseases such as ankylosing spondylitis, multiple sclerosis, Sjögrens syndrome and systemic lupus erythematosus. Conditions such as systemic hypertension and arthritis do not automatically exclude prospective participants.
  • Use of or a need for concurrent category S3 and above ocular medication at enrolment and/or during the clinical trial.
  • Use of or a need for any systemic medication or topical medications which may alter normal ocular findings / are known to affect a participant's ocular health / physiology or contact lens performance either in an adverse or beneficial manner at enrolment and/or during the clinical trial.
  • NB: Systemic antihistamines are allowed on an "as needed basis", provided they are not used prophylactically during the trial and at least 24 hours before the clinical trial product is used.
  • History of eye trauma
  • History of use of myopia control interventions such as Orthokeratology or eye surgery.
  • to atropine and caffeine such as pulmonary disease, heart conditions and ADHD
  • Known allergy or intolerance to ingredients to atropine eye-drops, xanthines and other derivatives of anti-muscarinic receptor agents.
  • Currently enrolled in another clinical trial.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
52 participants (actual)

Study arms

  • Active comparator
    Experimental BHVI2 eye drops

    20 participants will receive one drop per eye every night for four weeks.

    Drug: Experimental BHVI2

  • Active comparator
    0.02% Atropine eye drops

    20 participants will receive one drop per eye every night for four weeks.

    Drug: Atropine sulfate 0.02% eye drops

  • Active comparator
    Experimental BHVI2 plus 0.02% atropine

    20 participants will receive one drop per eye every night for four weeks.

    Combination Product: Combination eye drops

Interventions

  • DrugExperimental BHVI2

    Experimental BHVI2 eye drops

  • Atropine eye drops

  • Combination productCombination eye drops

    Combination eye drops with experimental BHVI2 plus 0.02% atropine

06

What researchers measure

Primary outcomes

  1. Change in pupillary diameter

    Measure and compare the photopic and mesopic pupil size (milimeters) before and after instillation of eye drops

    Time frame: At baseline, at two-week and one-month visits

  2. Change in accommodative amplitude

    Measure and compare the accommodative amplitude (diopters) before and after instillation of eye drops

    Time frame: At baseline, at two-week and one-month visits

07

Study locations

1 site
  • Department of Ophthalmology - An Sinh Hospital
    Ho Chi Minh City, 700000, Vietnam
08

References and documents

Publications

  • Bruce A. Re: Holden et al.: Global prevalence of myopia and high myopia and temporal trends from 2000 through 2050 (Ophthalmology 2016;123:1036-1042). Ophthalmology. 2017 Mar;124(3):e24-e25. doi: 10.1016/j.ophtha.2016.06.066. No abstract available. PubMed 28219507 ↗
  • Sankaridurg PR, Holden BA. Practical applications to modify and control the development of ametropia. Eye (Lond). 2014 Feb;28(2):134-41. doi: 10.1038/eye.2013.255. Epub 2013 Dec 6. PubMed 24310242 ↗
  • Huang J, Wen D, Wang Q, McAlinden C, Flitcroft I, Chen H, Saw SM, Chen H, Bao F, Zhao Y, Hu L, Li X, Gao R, Lu W, Du Y, Jinag Z, Yu A, Lian H, Jiang Q, Yu Y, Qu J. Efficacy Comparison of 16 Interventions for Myopia Control in Children: A Network Meta-analysis. Ophthalmology. 2016 Apr;123(4):697-708. doi: 10.1016/j.ophtha.2015.11.010. Epub 2016 Jan 27. PubMed 26826749 ↗
  • Shih YF, Chen CH, Chou AC, Ho TC, Lin LL, Hung PT. Effects of different concentrations of atropine on controlling myopia in myopic children. J Ocul Pharmacol Ther. 1999 Feb;15(1):85-90. doi: 10.1089/jop.1999.15.85. PubMed 10048351 ↗
  • Clark TY, Clark RA. Atropine 0.01% Eyedrops Significantly Reduce the Progression of Childhood Myopia. J Ocul Pharmacol Ther. 2015 Nov;31(9):541-5. doi: 10.1089/jop.2015.0043. Epub 2015 Jul 28. PubMed 26218150 ↗
  • Chatzistefanou KI, Mills MD. The role of drug treatment in children with strabismus and amblyopia. Paediatr Drugs. 2000 Mar-Apr;2(2):91-100. doi: 10.2165/00148581-200002020-00002. PubMed 10937461 ↗
  • Chen AM, Cotter SA. The Amblyopia Treatment Studies: Implications for Clinical Practice. Adv Ophthalmol Optom. 2016 Aug;1(1):287-305. doi: 10.1016/j.yaoo.2016.03.007. No abstract available. PubMed 28435934 ↗
  • Chia A, Lu QS, Tan D. Five-Year Clinical Trial on Atropine for the Treatment of Myopia 2: Myopia Control with Atropine 0.01% Eyedrops. Ophthalmology. 2016 Feb;123(2):391-399. doi: 10.1016/j.ophtha.2015.07.004. Epub 2015 Aug 11. PubMed 26271839 ↗
  • Tran HDM, Tran YH, Tran TD, Jong M, Coroneo M, Sankaridurg P. A Review of Myopia Control with Atropine. J Ocul Pharmacol Ther. 2018 Jun;34(5):374-379. doi: 10.1089/jop.2017.0144. Epub 2018 May 1. PubMed 29715053 ↗
  • Shih KC, Chan TC, Ng AL, Lai JS, Li WW, Cheng AC, Fan DS. Use of Atropine for Prevention of Childhood Myopia Progression in Clinical Practice. Eye Contact Lens. 2016 Jan;42(1):16-23. doi: 10.1097/ICL.0000000000000189. PubMed 26340385 ↗
  • Chia A, Chua WH, Cheung YB, Wong WL, Lingham A, Fong A, Tan D. Atropine for the treatment of childhood myopia: safety and efficacy of 0.5%, 0.1%, and 0.01% doses (Atropine for the Treatment of Myopia 2). Ophthalmology. 2012 Feb;119(2):347-54. doi: 10.1016/j.ophtha.2011.07.031. Epub 2011 Oct 2. PubMed 21963266 ↗
  • Chia A, Chua WH, Wen L, Fong A, Goon YY, Tan D. Atropine for the treatment of childhood myopia: changes after stopping atropine 0.01%, 0.1% and 0.5%. Am J Ophthalmol. 2014 Feb;157(2):451-457.e1. doi: 10.1016/j.ajo.2013.09.020. Epub 2013 Dec 4. PubMed 24315293 ↗
  • Chua WH, Balakrishnan V, Chan YH, Tong L, Ling Y, Quah BL, Tan D. Atropine for the treatment of childhood myopia. Ophthalmology. 2006 Dec;113(12):2285-91. doi: 10.1016/j.ophtha.2006.05.062. Epub 2006 Sep 25. PubMed 16996612 ↗
  • Shih YF, Hsiao CK, Chen CJ, Chang CW, Hung PT, Lin LL. An intervention trial on efficacy of atropine and multi-focal glasses in controlling myopic progression. Acta Ophthalmol Scand. 2001 Jun;79(3):233-6. doi: 10.1034/j.1600-0420.2001.790304.x. PubMed 11401629 ↗
  • North RV, Kelly ME. A review of the uses and adverse effects of topical administration of atropine. Ophthalmic Physiol Opt. 1987;7(2):109-14. doi: 10.1111/j.1475-1313.1987.tb01004.x. PubMed 2958765 ↗
  • Kennedy RH, Dyer JA, Kennedy MA, Parulkar S, Kurland LT, Herman DC, McIntire D, Jacobs D, Luepker RV. Reducing the progression of myopia with atropine: a long term cohort study of Olmsted County students. Binocul Vis Strabismus Q. 2000;15(3 Suppl):281-304. PubMed 11486796 ↗
  • Syniuta LA, Isenberg SJ. Atropine and bifocals can slow the progression of myopia in children. Binocul Vis Strabismus Q. 2001;16(3):203-8. PubMed 11511287 ↗
  • Wu PC, Yang YH, Fang PC. The long-term results of using low-concentration atropine eye drops for controlling myopia progression in schoolchildren. J Ocul Pharmacol Ther. 2011 Oct;27(5):461-6. doi: 10.1089/jop.2011.0027. Epub 2011 Aug 4. PubMed 21815829 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2018 to primary completion in Feb 2019, 4 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 27, 2018
First posted
Oct 1, 2018
StartActual
Oct 1, 2018
Primary completionActual
Feb 2, 2019
CompletionActual
Jun 30, 2019
Last update
Feb 12, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 12, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03690414
Lead sponsor
Hai Yen Eye Care
Collaborators
Brien Holden Vision
Responsible party
Sponsor
First posted
Oct 1, 2018
Start date
Oct 1, 2018
Primary completion
Feb 2, 2019
Completion
Jun 30, 2019
Last update
Feb 12, 2020

Study contacts

Huy D.M Tran, MD, MSc
principal investigator · Hai Eye Eye Care

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Atropine

Start the discussion